Inventor
ROBERTS PATRICK JOSEPH
US23 patents
⚠️ This page may combine multiple inventors who share the name “ROBERTS PATRICK JOSEPH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
G1 THERAPEUTICS INC
22 patentsUS9527857B2Dec 27, 2016
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
G1 THERAPEUTICS INC31 citations98
US9487530B2Nov 8, 2016
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC36 citations98
US9464092B2Oct 11, 2016
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC29 citations98
US10434104B2Oct 8, 2019
HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
G1 THERAPEUTICS INC7 citations92
US10085992B2Oct 2, 2018
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC16 citations92
US10076523B2Sep 18, 2018
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
G1 THERAPEUTICS INC15 citations92
US9931345B2Apr 3, 2018
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC14 citations92
US11654148B2May 23, 2023
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
G1 THERAPEUTICS INC4 citations86
US11717523B2Aug 8, 2023
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC3 citations84
US11090306B2Aug 17, 2021
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
G1 THERAPEUTICS INC9 citations84
US11040042B2Jun 22, 2021
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC5 citations84
US10966984B2Apr 6, 2021
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC5 citations84
US10925878B2Feb 23, 2021
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
G1 THERAPEUTICS INC5 citations84
US10709711B2Jul 14, 2020
Highly active anti-neoplastic and anti-proliferative agents
G1 THERAPEUTICS INC6 citations84
US10660896B2May 26, 2020
Transient protection of normal cells during chemotherapy
G1 THERAPEUTICS INC5 citations84
US10376519B2Aug 13, 2019
Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
G1 THERAPEUTICS INC5 citations84
US9717735B2Aug 1, 2017
Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
G1 THERAPEUTICS INC16 citations84
US10413547B2Sep 17, 2019
Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors
G1 THERAPEUTICS INC11 citations83
US11529352B2Dec 20, 2022
Preservation of immune response during chemotherapy regimens
G1 THERAPEUTICS INC6 citations82
US10231969B2Mar 19, 2019
Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors
G1 THERAPEUTICS INC12 citations82
US12285431B2Apr 29, 2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
G1 THERAPEUTICS INC2 citations73
US11446295B2Sep 20, 2022
Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors
G1 THERAPEUTICS INC4 citations71